TRISH’s Diversity Partnership Solicitation Program selected two research teams to receive funding and support. Photo via BCM.edu

A local organization announced two newly funded partnerships to advance research and innovation within space health.

The Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine has announced — along with partner organizations Caltech and the Massachusetts Institute of Technology — $300,000 in funding for teams at Texas State University and the University of Florida.

The two schools have been named awardees of TRISH’s Diversity Partnership Solicitation Program that was founded to support TRISH’s ongoing commitment to increasing engagement from underrepresented groups in the field of space health research.

“We go to space to improve life everywhere, and we must do so representing everyone,” says Dr. Asha S. Collins, chair of TRISH’s Diversity Advisory Board, in a news release. “The members of TRISH’s Diversity Advisory Board helped select two strong partners through our Diversity Partnership Program, and their work will move us closer to achieving that reality for the future of space exploration for all.”

The two projects that were selected for the program include:

  • B-SURE: Boosting Spaceflight Underrepresented Researcher Equity:
    • Principal Investigator: Dr. Rachael Seidler, University of Florida
    • Co-Investigators: Drs. Josephine Allen and Christine Wegner, University of Florida; Dr. Ana Diaz Artiles, Texas A&M University.
    • Dr. Rachael Seidler and her University of Florida team is partnered with Texas A&M University to survey the field and build a database of underrepresented researchers interested in pursuing space health research and a second database of leaders in this field open to new collaborators and mentorship.
  • Lyndon B. Johnson Institute for STEM Education and Research Space Health Inclusion Partnership
    • Principal Investigator: Dr. Kristina Collins, Texas State University
    • Co-Investigators and Collaborators: Drs. Leslie Huling, Barbie Buckner and Sara Torres, Deepika Sangam, Texas State University.
    • Dr. Collins and her team will use Texas State's existing virtual education tools to launch a set of novel space health content with digital badges and certifications.

Each of the projects were selected for "their innovative means of facilitating underrepresented researcher engagement," per the news release. Both teams will establish a cohort of underrepresented researchers dedicated to innovating future applications for space health research funding.

TRISH is funded by NASA’s Human Research Program and seeks both early stage and translation-ready research and technology to protect and improve the health and performance of space explorers. Last month, TRISH released a free-to-watch documentary on space health.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”